There is a need for safe and effective topical therapeutic agents for the treatment of atopic dermatitis (AD), whose prevalence is increasing. SIG1322 is our 2nd isoprenylcysteine (IPC) drug development candidate. Funded primarily through SBIR grants via the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) we are in the preclinical/discovery phase for this molecule.
Proposed Mechanism of Action
SIG1322 is an anti-inflammatory molecule which has shown efficacy in in vitro and in vivo models of allergic contact dermatitis when applied topically.